Abstract
Purpose
To evaluate a radiomic approach for the stratification of diffuse gliomas with distinct prognosis and provide additional resolution of their clinicopathological and molecular characteristics.
Methods
For this retrospective study, a total of 704 radiomic features were extracted from the multi-channel MRI data of 166 diffuse gliomas. Survival-associated radiomic features were identified and submitted to distinguish glioma subtypes using consensus clustering. Multi-layered molecular data were used to observe the different clinical and molecular characteristics between radiomic subtypes. The relative profiles of an array of immune cell infiltrations were measured gene set variation analysis approach to explore differences in tumor immune microenvironment.
Results
A total of 6 categories, including 318 radiomic features were significantly correlated with the overall survival of glioma patients. Two subgroups with distinct prognosis were separated by consensus clustering of radiomic features that significantly associated with survival. Histological stage and molecular factors, including IDH status and MGMT promoter methylation status were significant differences between the two subtypes. Furthermore, gene functional enrichment analysis and immune infiltration pattern analysis also hinted that the inferior prognosis subtype may more response to immunotherapy.
Conclusion
A radiomic model derived from multi-parameter MRI of the gliomas was successful in the risk stratification of diffuse glioma patients. These data suggested that radiomics provided an alternative approach for survival estimation and may improve clinical decision-making.
Similar content being viewed by others
References
Aerts HJ et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006. https://doi.org/10.1038/ncomms5006
Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr (2012) Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 35:385–389. https://doi.org/10.1097/CJI.0b013e3182562d59
Akkus Z, Ali I, Sedlar J, Agrawal JP, Parney IF, Giannini C, Erickson BJ (2017) Predicting deletion of chromosomal arms 1p/19q in low-grade gliomas from mr images using machine intelligence. J Digit Imaging 30:469–476. https://doi.org/10.1007/s10278-017-9984-3
Bakas S et al (2016) GLISTRboost: combining multimodal MRI segmentation registration, and biophysical tumor growth modeling with gradient boosting machines for glioma segmentation. Brainlesion 9556:144–155. https://doi.org/10.1007/978-3-319-30858-6_1
Bakas S et al (2017) Advancing the cancer genome atlas glioma MRI collections with expert segmentation labels and radiomic features. Sci Data 4:170117. https://doi.org/10.1038/sdata.2017.117
Berghoff AS et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:1064–1075. https://doi.org/10.1093/neuonc/nou307
Berghoff AS et al (2017) Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol 19:1460–1468. https://doi.org/10.1093/neuonc/nox054
Bi WL et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127–157. https://doi.org/10.3322/caac.21552
Binder H et al (2019) DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Acta Neuropathol Commun 7:59. https://doi.org/10.1186/s40478-019-0704-8
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Brennan C (2011) Genomic profiles of glioma. Curr Neurol Neurosci Rep 11:291–297. https://doi.org/10.1007/s11910-011-0198-7
Ceccarelli M et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
Clark K et al (2013) The cancer imaging archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26:1045–1057. https://doi.org/10.1007/s10278-013-9622-7
Doshi J, Erus G, Ou Y, Gaonkar B, Davatzikos C (2013) Multi-atlas skull-stripping. Acad Radiol 20:1566–1576. https://doi.org/10.1016/j.acra.2013.09.010
Eckel-Passow JE et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279
Eder K, Kalman B (2014) Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res 20:777–787. https://doi.org/10.1007/s12253-014-9833-3
Yan W et al (2012) Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese glioma cooperative group. Neuro Oncol 14:1432–1440. https://doi.org/10.1093/neuonc/nos263
Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158–2167. https://doi.org/10.1158/1078-0432.CCR-06-2070
Ferlay J et al (2018) (2019) Estimating the global cancer incidence and mortality in GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937
Garber ST et al (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18:1357–1366. https://doi.org/10.1093/neuonc/now132
Gooya A, Pohl KM, Bilello M, Cirillo L, Biros G, Melhem ER, Davatzikos C (2012) GLISTR: glioma image segmentation and registration. IEEE Trans Med Imaging 31:1941–1954. https://doi.org/10.1109/TMI.2012.2210558
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7. https://doi.org/10.1186/1471-2105-14-7
Hartmann C et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474. https://doi.org/10.1007/s00401-009-0561-9
Hastie T TR, Narasimhan B, Chu G (2019) impute: impute: Imputation for microarray data. R package version 1.60.0.
Itakura H et al. (2015) Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med 7:303ra138. Doi:10.1126/scitranslmed.aaa7582.
Jenkinson M, Smith S (2001) A global optimisation method for robust affine registration of brain images. Med Image Anal 5:143–156. https://doi.org/10.1016/s1361-8415(01)00036-6
Jenkinson M, Bannister P, Brady M, Smith S (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825–841. https://doi.org/10.1016/s1053-8119(02)91132-8
Kohanbash G et al (2017) Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 127:1425–1437. https://doi.org/10.1172/JCI90644
Lambin P et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446. https://doi.org/10.1016/j.ejca.2011.11.036
Lambin P et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762. https://doi.org/10.1038/nrclinonc.2017.141
Liu J et al (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(400–416):e411. https://doi.org/10.1016/j.cell.2018.02.052
Louis DN et al (2016) The World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Mirzaei R, Sarkar S, Yong VW (2017) T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. Trends Immunol 38:104–115. https://doi.org/10.1016/j.it.2016.11.005
Nie D et al (2019) Multi-channel 3D deep feature learning for survival time prediction of brain tumor patients using multi-modal. Neuroimages Sci Rep 9:1103. https://doi.org/10.1038/s41598-018-37387-9
Noushmehr H et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522. https://doi.org/10.1016/j.ccr.2010.03.017
Olar A et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol 129:585–596. https://doi.org/10.1007/s00401-015-1398-z
Patel AP et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401. https://doi.org/10.1126/science.1254257
Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. https://doi.org/10.1016/j.ccr.2006.02.019
Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P (2017) Radiomic features from the peritumoral brain parenchyma on treatment-naive multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: preliminary findings. Eur Radiol 27:4188–4197. https://doi.org/10.1007/s00330-016-4637-3
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17:143–155. https://doi.org/10.1002/hbm.10062
Smith SM, Brady JM (1997) SUSAN—A new approach to low level image processing. Int J Comput Vision 23:45–78
Spyridon Bakas HA et al (2017a) Segmentation labels and radiomic features for the pre-operative scans of the TCGA–GBM collection The Cancer Imaging Archive. Nat Sci Data 4:170117. https://doi.org/10.1038/sdata.2017.117
Spyridon Bakas HA et al (2017b) Segmentation labels and radiomic features for the pre-operative scans of the TCGA–LGG collection The Cancer Imaging Archive. Nat Sci Data 4:170117. https://doi.org/10.1038/sdata.2017.117
Sulman EP, Aldape K (2011) The use of global profiling in biomarker development for gliomas. Brain Pathol 21:88–95. https://doi.org/10.1111/j.1750-3639.2010.00456.x
Tamborero D et al (2018) A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res 24:3717–3728. https://doi.org/10.1158/1078-0432.CCR-17-3509
Tan Y et al (2019) A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery. Eur Radiol 29:3325–3337. https://doi.org/10.1007/s00330-019-06056-4
van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120:297–304. https://doi.org/10.1007/s00401-010-0725-7
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153. https://doi.org/10.2353/ajpath.2009.080958
Wen PY, Huse JT (2017) 2016 World health organization classification of central nervous system. Tumors Continuum (Minneap Minn) 23:1531–1547. https://doi.org/10.1212/CON.0000000000000536
Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572–1573. https://doi.org/10.1093/bioinformatics/btq170
Wu S, Meng J, Yu Q, Li P, Fu S (2019) Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas. J Cancer Res Clin Oncol 145:543–550. https://doi.org/10.1007/s00432-018-2787-1
Zhang X et al (2018) Radiomics strategy for molecular subtype stratification of lower-grade glioma: detecting IDH and TP53 mutations based on multimodal MRI. J Magn Reson Imaging 48:916–926. https://doi.org/10.1002/jmri.25960
Acknowledgements
The results shown here are parts based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga and TCIA database: https://www.cancerimagingarchive.net/. Special thanks to the authors (Spyridon Bakas, Hamed Akbari, Aristeidis Sotiras, Michel Bilello, Martin Rozycki, Justin S. Kirby, John B. Freymann, Keyvan Farahani & Christos Davatzikos) of “Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features”. The public online available data are valuable for related research work.
Funding
This research was supported by Guangxi Degree and Postgraduate Education Reform and Development Research Projects, China (JGY2019050), Guangxi Zhuang Autonomous Region Health and Family Planning Commission Self-financed Scientific Research Project (Z20180979).
Author information
Authors and Affiliations
Contributions
Conception and design: HY and GC. Development of methodology: PL, YTP, and RZG. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, and computational analysis): YW, XJL, SNH, YYF, and ZXW. Writing, review, and/or revision of the manuscript: PL, ZGH, HY, and GC. Study supervision: HY and GC.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Not applicable.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lin, P., Peng, Yt., Gao, Rz. et al. Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value. J Cancer Res Clin Oncol 146, 1253–1262 (2020). https://doi.org/10.1007/s00432-020-03153-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03153-6